ACLARIS THERAPEUTICS INC's ticker is ACRS and the CUSIP is 00461U105. A total of 153 filers reported holding ACLARIS THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.70 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $272,069 | -35.3% | 39,718 | -2.1% | 0.00% | – |
| Q2 2023 | $420,701 | +36.4% | 40,569 | +6.4% | 0.00% | – |
| Q1 2023 | $308,529 | -29.5% | 38,137 | +37.3% | 0.00% | – |
| Q4 2022 | $437,583 | -4.0% | 27,783 | -4.1% | 0.00% | – |
| Q3 2022 | $456,000 | +31.8% | 28,985 | +17.0% | 0.00% | – |
| Q2 2022 | $346,000 | -16.6% | 24,769 | +2.9% | 0.00% | – |
| Q1 2022 | $415,000 | +17.2% | 24,076 | -1.1% | 0.00% | – |
| Q4 2021 | $354,000 | -95.5% | 24,339 | -94.5% | 0.00% | -100.0% |
| Q3 2021 | $7,898,000 | +2156.6% | 438,802 | +2103.3% | 0.00% | – |
| Q2 2021 | $350,000 | -98.5% | 19,916 | -97.8% | 0.00% | -100.0% |
| Q1 2021 | $22,857,000 | +3678.0% | 907,034 | +870.4% | 0.01% | – |
| Q4 2020 | $605,000 | +141.0% | 93,472 | -4.1% | 0.00% | – |
| Q3 2020 | $251,000 | +54.0% | 97,516 | -3.2% | 0.00% | – |
| Q2 2020 | $163,000 | +37.0% | 100,740 | -12.2% | 0.00% | – |
| Q1 2020 | $119,000 | +133.3% | 114,757 | +321.6% | 0.00% | – |
| Q4 2019 | $51,000 | +64.5% | 27,217 | -6.2% | 0.00% | – |
| Q3 2019 | $31,000 | -53.0% | 29,022 | -3.8% | 0.00% | – |
| Q2 2019 | $66,000 | -64.7% | 30,162 | -3.4% | 0.00% | – |
| Q1 2019 | $187,000 | -97.6% | 31,234 | -94.3% | 0.00% | -100.0% |
| Q3 2018 | $7,904,000 | -31.3% | 544,334 | -5.5% | 0.00% | -50.0% |
| Q2 2018 | $11,502,000 | +14.0% | 575,965 | +0.0% | 0.00% | 0.0% |
| Q1 2018 | $10,091,000 | -30.1% | 575,954 | -1.6% | 0.00% | -20.0% |
| Q4 2017 | $14,432,000 | -4.4% | 585,254 | +0.0% | 0.01% | -16.7% |
| Q3 2017 | $15,104,000 | -8.6% | 585,197 | -4.0% | 0.01% | +20.0% |
| Q2 2017 | $16,533,000 | -15.3% | 609,600 | -6.9% | 0.01% | -16.7% |
| Q1 2017 | $19,531,000 | +15.3% | 654,976 | +4.9% | 0.01% | 0.0% |
| Q4 2016 | $16,944,000 | – | 624,323 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management V, LLC | 1,258,243 | $8,618,965 | 13.75% |
| Foresite Capital Management IV, LLC | 2,808,034 | $19,235,033 | 10.68% |
| Bain Capital Life Sciences Investors, LLC | 3,400,000 | $23,290,000 | 2.60% |
| GREAT POINT PARTNERS LLC | 1,691,768 | $11,588,611 | 2.11% |
| Samsara BioCapital, LLC | 696,171 | $4,768,771 | 1.46% |
| Altium Capital Management LP | 403,000 | $2,760,550 | 1.44% |
| BVF INC/IL | 7,064,736 | $48,393,442 | 1.30% |
| Aisling Capital Management LP | 434,455 | $2,976,017 | 1.23% |
| GREAT POINT PARTNERS LLC | 700,000 | $4,795,000 | 0.87% |
| VR Adviser, LLC | 1,040,754 | $7,129,165 | 0.75% |